Clinical Evidence: Weight Loss
up to 22.5% weight reduction -- the SURMOUNT program and head-to-head data vs semaglutide
Closing the Surgery Gap
The SURMOUNT program tested tirzepatide specifically for obesity and overweight in adults without diabetes. SURMOUNT-1 delivered the headline: 22.5% mean body-weight loss at the 15mg dose over 72 weeks, with more than a third of participants losing 25% or more. SURMOUNT-5 provided the first head-to-head comparison against semaglutide 2.4mg for weight management. This unit breaks down each trial, examines weight maintenance data, and evaluates what the body-composition evidence actually shows.
SURMOUNT Results
Explore weight-loss outcomes across the SURMOUNT trial program and compare dose-response curves.